Short Interest in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Increases By 15.0%

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 131,600 shares, a growth of 15.0% from the October 31st total of 114,400 shares. Currently, 0.8% of the shares of the company are sold short. Based on an average daily trading volume, of 36,100 shares, the days-to-cover ratio is currently 3.6 days.

Analyst Upgrades and Downgrades

CYTH has been the subject of several research reports. Maxim Group reissued a “hold” rating on shares of Cyclo Therapeutics in a research report on Tuesday, August 27th. Ascendiant Capital Markets dropped their price objective on shares of Cyclo Therapeutics from $2.60 to $0.95 and set a “buy” rating on the stock in a report on Monday, August 26th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $0.95 target price (down previously from $3.00) on shares of Cyclo Therapeutics in a research note on Friday, August 23rd.

Cyclo Therapeutics Stock Performance

Shares of NASDAQ CYTH traded down $0.02 during trading hours on Tuesday, reaching $0.66. The stock had a trading volume of 12,809 shares, compared to its average volume of 22,113. Cyclo Therapeutics has a twelve month low of $0.59 and a twelve month high of $2.12. The business’s fifty day moving average is $0.73 and its two-hundred day moving average is $0.97.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.